INTRODUCTION
============

ADP-ribosylation is a type of protein posttranslational modification initiated by a group of enzymes named poly(ADP-ribose) (PAR) polymerases (PARPs). The PARPs can hydrolyze nicotinamide adenine dinucleotide and transfer ADP-ribose to substrates. There are two types of ADP-ribosylation: mono-ADP-ribosylation is a modification in which only one unit of ADP-ribose is transferred to Glu/Asp/Lys residues of target proteins, while poly-ADP-ribosylation (PARsylation) involves several units of ADP-ribose being transferred to specific residues of target proteins to form ADP-ribose polymers ([@b24-molcell-37-1-9-2]; [@b65-molcell-37-1-9-2]).

Posttranslational modification by PARsylation regulates cellular functions *via* several mechanisms. For example, ribosylation of some DNA repair proteins is required for their recruitment to DNA damage sites; ribosylation of substrate proteins can also affect protein-protein interactions, especially in the case of PAR-binding proteins that specifically recognize the ribosylated target proteins; ribosylation of target proteins can also facilitate the recruitment of E3 ubiquitin ligase, which promotes target protein degradation *via* proteasomal pathway. Through these distinct mechanisms, PARsylation participates in a wide range of cellular processes, including DNA damage response, transcription, chromatin remodeling, telomere protection, cell proliferation, cell death, and tumorigenesis. In this review, we summarize our current understanding of PARP family members and their functions in various aspects of cellular processes. In addition, we categorize the PAR recognition domains and describe the importance of PAR-binding motifs in signal transduction. Moreover, we introduce the unique functions of several enzymes that are specifically involved in the removal of ADP-ribosylation, which indicates the reversible nature of ADP-ribo-sylation as a signaling moiety.

THE PARP FAMILY MEMBERS AND THEIR DIVERSE CELLULAR FUNCTIONS
============================================================

The PARP family has 17 members, which can be categorized into five subgroups according to their domains or functions ([Fig. 1](#f1-molcell-37-1-9-2){ref-type="fig"}): DNA damage-dependent PARPs (PARP1, PARP2, and PARP3), tankyrases (tankyrase1/PARP5a and tankyrase2/PARP5b), CCCH-type PARPs (PARP7, PARP12, and PARP13), macro-PARPs \[B-aggressive lymphoma 1 (BAL1)/PARP9, BAL2/PARP14, and BAL3/PARP15\], and other PARPs (PARP4, PARP6, PARP8, PARP10, PARP11, and PARP16) ([@b18-molcell-37-1-9-2]).

DNA damage-dependent PARPs
--------------------------

The DNA damage-dependent PARPs are normally activated by DNA breaks. PARP1, the first identified and the best understood PARP, is a nuclear protein and has three known functional domains: the DNA-binding domain at its very N-terminal region (Zinc finger domain); the auto-modification domain in the middle (i.e. BRCT domain), which is also where PARP1 interacts with its substrates as well as the region that undergoes auto-modification/poly-ribosylation; and the C-terminal catalytic domain, which binds to nicotinamide adenine dinucleotide and promotes the formation of ADP-ribose chain on its substrates as well as itself ([@b58-molcell-37-1-9-2]). PARP1 is required for DNA single-strand break repair (SSBR) and base-excision repair (BER) by binding to and recruiting XRCC1 to DNA damage site ([@b51-molcell-37-1-9-2]). In addition, PARP1 also interacts with DNA double-strand break repair proteins such as Ku and DNA-PKcs and participates in NHEJ (nonhomologous end joining) repair pathway ([@b35-molcell-37-1-9-2]; [@b39-molcell-37-1-9-2]; [@b61-molcell-37-1-9-2]). Thus, PARP1 inhibitors have been developed for cancer treatment, since they would sensitize tumors to radiation and/or chemotherapeutic agents that induce DNA strand breaks. More recently, PARP inhibition has been shown to cause synthetic lethality in homologous recombination deficient tumor cells, such as BRCA1 or BRCA2 deficient cells, by blocking base excision repair and therefore has been used in clinic trials for the treatment of BRCA-deficient tumors ([@b7-molcell-37-1-9-2]; [@b15-molcell-37-1-9-2]; [@b52-molcell-37-1-9-2]).

PARP2 can also be activated by DNA strand breaks ([@b3-molcell-37-1-9-2]). PARP1- and PARP2-knockout cells are sensitive to DNA damage, exhibiting marked increased chromatin instability and repair defects ([@b64-molcell-37-1-9-2]). PARP1 and PARP2 knockout mice display similar hypersensitivity to ionizing radiation ([@b12-molcell-37-1-9-2]), suggesting that both PARP1 and PARP2 are involved in DNA damage repair. Likewise, PARP3 is similar to PARP1 and PARP2, since its activity is also stimulated by DNA strand breaks. Recent study suggests that PARP3, and APLF (aprataxin and PNK-like factor) work cooperatively to facilitate double-strand break repair by promoting DNA ligation ([@b60-molcell-37-1-9-2]). Therefore, this group of PARPs, PARP1/2/3, is activated by DNA damage and plays critical roles in DNA damage signaling and DNA repair.

PARP1 is the major PARP responding to DNA damage. However, comparing to PARP1 or PARP2 deficient mice, which are sensitive to DNA damage, the PARP1/2 double KO mice are embryonic lethal ([@b12-molcell-37-1-9-2]), indicating that PARP1 and PARP2 at least share some redundant functions *in vivo*. Whether PARP1/2/3 work together or separately in DNA damage repair remains unknown. In response to DNA damage, many DNA damage repair proteins as well as PARP1 are recruited to DNA damage sites. At the same time, PARP1 catalyzes ADP-ribosylation of its target proteins at sites of DNA damage. Although the connections between ADP-ribosylation and the recruitment for these DNA damage repair proteins have not been fully elucidated, recent studies suggest that a subset of BRCT and FHA domains may have PAR-binding activity and thus participate in damage-induced recruitment of DNA damage checkpoint and repair proteins ([@b37-molcell-37-1-9-2]).

Tankyrases
----------

Tankyrase1/PARP5a and tankyrase2/PARP5b are closely related, both having long ankyrin repeat regions at the N-terminal region, which are required for protein-protein interaction. They also contain sterile alpha modules in the middle, which is required for homodimerization and heterodimerization, and catalytic PARP domains at the C-terminus ([@b25-molcell-37-1-9-2]). The difference between these two proteins is that tankyrase 2 lacks the homopolymeric tracks of the His, Pro, and Ser domain with unknown function, which is present at the N-terminus of tankyrase 1. Otherwise, tankyrase 1 and tankyrase 2 have very similar domain structures and functions ([@b62-molcell-37-1-9-2]).

Tankyrases are known to have diverse functions by targeting different substrates for ADP-ribosylation. Researchers first identified that tankyrases affect telomere extension by PARsylating TRF1, which negatively regulates telomere extension ([@b70-molcell-37-1-9-2]). Mechanistically, it is known that tankyrases interact with and PARsylate TRF1, promoting the proteasomal degradation of TRF1 and thus leading to its release from telomeres to promote telomere extension ([@b69-molcell-37-1-9-2]). Tankyrase 1 can also PARsylate nuclear mitotic apparatus protein (NUMA) to control sister chromatid cohesion ([@b8-molcell-37-1-9-2]). In addition, tankyrase 1 has also been shown to PARsylate Miki to promote prometaphase progression ([@b50-molcell-37-1-9-2]). Moreover, Tankyrase1 can PARsylate 3BP2, leading to its degradation, and thus facilitating normal bone formation ([@b36-molcell-37-1-9-2]).

Tankyrases have recently been recognized as potential drug targets for cancer treatment ([@b56-molcell-37-1-9-2]). Tankyrases PARsylate and promote the proteasome-dependent degradation of axin, which leads to the activation of the Wnt signaling pathway ([@b26-molcell-37-1-9-2]). Mechanistically, it is now known that the PAR-binding E3 ligase RNF146 mediates the ubiquitination and degradation of PARsylated axin ([@b78-molcell-37-1-9-2]). Moreover, Zhang and colleagues demonstrated that the tankyrase inhibitor XAV939 could stabilize axin1/2 and thus inhibit the Wnt signaling pathway ([@b26-molcell-37-1-9-2]). Therefore, tankyrase inhibitors are being actively pursued as possible anti-cancer agents ([@b56-molcell-37-1-9-2]).

CCCH-type PARPs
---------------

The CCCH-type PARPs PARP7, PARP12, and PARP13 have a common Cys-Cys-Cys-His zinc finger domain and common WWE domains. PARP7/TiPARP is a mono-ADP-ribosyltransferase that is regulated by the aryl hydrocarbon receptor (AHR). This CCCH-type PARP co-localizes with the AHR in the nucleus and transcriptionally represses AHR ([@b42-molcell-37-1-9-2]). PARP12 is involved in the regulation of Venezuelan equine encephalitis virus (VEEV) replication ([@b6-molcell-37-1-9-2]). PARP13 is catalytically inactive; but an isoform of PARP13 lacking PARP domain (ZAP) has been shown to interact with viral RNA and prohibit viral RNA accumulation ([@b17-molcell-37-1-9-2]). Overall, this family of PAPRs has not been extensively studied. However, given the presence of CCCH Zinc finger domain and the PAR-binding WWE domain on this group of PARPs, it is likely that these PARPs may engage in some interesting PAR-dependent regulations that need to be further elucidated.

Macro-PARPs
-----------

Macro-PARPs are PARPs that contain Macro domains, which include PARP9, PARP14 and PARP15. The macro-PARP BAL1/PARP9 is a transcription modulator that is differentially expressed in diffuse large B-cell lymphoma cells ([@b30-molcell-37-1-9-2]). More recently, BAL1/PARP9 and it partner E3 ligase BBAP have been shown to participate in DNA damage response by mediating protein ubiquitination, which is involved in the recruitment of double-strand break repair proteins 53BP1 and BRCA1 ([@b74-molcell-37-1-9-2]).

BAL2/PARP14 contains three macrodomains and a WWE domain. Similar to PARP9, PARP14 has also been suggested to regulate gene transcription. It interacts with STAT6 and increases STAT6 transcriptional activity ([@b44-molcell-37-1-9-2]). BAL3/PARP15 contains two macrodomains. It can bind to mono-ADP-ribose or poly-ADP-ribose *via* its macrodomain and exhibit mono-ADP-ribosylation activity ([@b72-molcell-37-1-9-2]). However, there is no known function of PARP15.

Other PARPs
-----------

There are a number of PARPs that do not share any common domain structures. These include PARP4, PARP6, PARP8, PARP10, PARP11, and PARP16. PARP4/vPARP is the largest protein in the PARP family and is a component of the vaults, which is 13 MDa ribonucleoprotein complex present in the cytoplasm of cells ([@b55-molcell-37-1-9-2]). PARP4/vPARP-deficient mice exhibited increased formation of carcinogen-induced tumors ([@b55-molcell-37-1-9-2]), indicating that PARP4 may have an unknown function in tumor suppression. PARP6 has mono-ADP-ribosylation activity and negatively regulates cellular proliferation ([@b71-molcell-37-1-9-2]). PARP8 and PARP11 also possess mono-ADP-ribosylation activity, but little is known about the functions of these two proteins ([@b63-molcell-37-1-9-2]). PARP10 lacks glutamate residue within its catalytic domain. It has mono-ADP-ribosylation activity but cannot promote poly-ADP-ribosylation ([@b33-molcell-37-1-9-2]). This PARP interacts with Myc and inhibits c-Myc- and E1A-mediated transformation ([@b76-molcell-37-1-9-2]). PARP16 acts as a mono-ADP-ribosyltransferase and negatively regulates the protein level of karyopherin-β1 ([@b13-molcell-37-1-9-2]). PARP16 promotes ADP-ribosylation of PERK and IRE1α and is required for their activation during endoplasmic reticulum stress ([@b31-molcell-37-1-9-2]). Overall, these PARPs have not been widely studied and we only have a glimpse of their cellular and physiological functions.

THE PAR RECOGNITION DOMAINS
===========================

The PAR-binding motif
---------------------

The PAR-binding motif (PBM) is the first identified PAR recognition domain ([@b54-molcell-37-1-9-2]). It is present in most of the known PAR-binding proteins. The consensus PBM sequence is refined to an eight-amino-acid motif: \[HKR\]-X-X-\[AIQVY\]-\[KR\]-\[AILV\]-\[FILPV\] ([@b16-molcell-37-1-9-2]). The PBM-containing proteins are involved in diverse cellular processes. For example, both P53 and P21 contain PBM and are key factors in the regulation of cell cycle progression and proliferation, especially in response to stresses like DNA damage ([@b14-molcell-37-1-9-2]). In addition, x-ray repair cross-complementing protein 1 (XRCC1) also has PBM and is rapidly recruited to DNA damage sites, where PARP1-mediated poly-ADP-ribosylation occurs ([@b54-molcell-37-1-9-2]). Apoptosis-inducing factor 1 (AIF1), another PBM-containing PAR-binding protein, is critically important for PARP1-induced cell death ([@b77-molcell-37-1-9-2]). Thus, many of these proteins are involved in certain aspects of DNA damage response.

The macrodomain
---------------

The macrodomain contains 140--190 residues and was initially discovered in histone variant macroH2A ([@b53-molcell-37-1-9-2]). The macrodomain-containing proteins currently have 10 members and can be categorized into four groups ([@b10-molcell-37-1-9-2]; [@b23-molcell-37-1-9-2]) ([Fig. 2](#f2-molcell-37-1-9-2){ref-type="fig"}). As discussed above, PARP9, PARP14, and PARP15, which make up the BAL1 family, contain two or three macrodomains. PARP14 and PARP15 exhibit mono-ADP-ribosylation activity while PARP9 seems to be inactive ([@b1-molcell-37-1-9-2]). The MacroD1, MacroD2, and C6orf130 have recently been shown to possess enzymatic activity and participate in the removal of mono-ADP-ribose from substrate proteins ([@b29-molcell-37-1-9-2]; [@b57-molcell-37-1-9-2]; [@b67-molcell-37-1-9-2]). Additionally, macroH2A1 and macroH2A2, which are histone subunits, function in transcriptional regulation ([@b9-molcell-37-1-9-2]; [@b11-molcell-37-1-9-2]). Finally, CHD1L is an ATP-dependent chromatin remodeler ([@b21-molcell-37-1-9-2]), while GDAP2 is induced by ganglioside synthase expression ([@b47-molcell-37-1-9-2]). Besides MarcoD1/2 and C6orf130 that have terminal ADP-ribose protein glycohydrolase activity, the functional significance of other macrodomains has not been extensively studied.

PAR-binding zinc finger
-----------------------

PAR-binding zinc finger (PBZ) is a recently identified zinc finger domain that binds to PAR ([@b2-molcell-37-1-9-2]). There are three known PBZ-containing proteins. Checkpoint protein with FHA and RING domains (CHFR) is a tumor suppressor that functions in an early mitotic checkpoint by preventing cells from entering into mitosis ([@b66-molcell-37-1-9-2]). APLF is also an FHA domain-containing protein that participates in DNA damage responsive pathway ([@b28-molcell-37-1-9-2]; [@b59-molcell-37-1-9-2]). Mutation of PBZ domain in either CHFR or APLF abolishes their ability to bind to PAR ([@b2-molcell-37-1-9-2]). Moreover, PBZ domain mutant of CHFR abrogates its function in mitotic checkpoint control ([@b2-molcell-37-1-9-2]), but the underlying mechanism remains unclear. Another PBZ-containing protein in mammals is the DNA cross-link repair protein SNM1A ([@b48-molcell-37-1-9-2]).

The WWE domain
--------------

The WWE domain is the most interesting of the recently identified PAR-binding domains, as some WWE-containing proteins exhibit E3 ligase activity and are critical not only for the recognition of PARsylated proteins but also mediating ubiquitination and proteasomal degradation of these modified proteins ([@b5-molcell-37-1-9-2]). The WWE domain-containing proteins can be categorized into three groups ([Fig. 3](#f3-molcell-37-1-9-2){ref-type="fig"}). The first group consists of PARP7, PARP11, PARP12, PARP13, and PARP14, all of which have one or two WWE domains and a PARP domain ([@b73-molcell-37-1-9-2]). The second group consists of the E3-ubiquitin ligases Deltex1, Deltex2, Deltex4, HUWE1, TRIP12, and RNF146/Iduna. Deltex1, Deltex2, and Deltex4 are homologs of *Drosophila* Deltex, which is a critical regulator of Notch signaling ([@b43-molcell-37-1-9-2]). HUWE1 is the E3 ligase for apoptotic protein Mcl1 ([@b80-molcell-37-1-9-2]). TRIP12 is thought to regulate the accumulation of RNF168 and downstream DNA damage pathways ([@b22-molcell-37-1-9-2]). Of the proteins in this group, only RNF146/Iduna has exhibited a functional connection between its E3 ligase activity and ADP-ribosylation. RNF146 protects neurons by interfering with PAR polymer-induced cell death ([@b4-molcell-37-1-9-2]). RNF146 also protects against cell death induced by DNA damage *via* PAR-dependent ubiquitination and proteasomal degradation of PARP1 ([@b32-molcell-37-1-9-2]). The most exciting finding regarding RNF146 is that it can regulate the WNT signaling pathway by mediating tankyrase-dependent degradation of axin. RNF146 binds directly to ADP-ribosylated axin and promotes axin ubiquitination and degradation ([@b79-molcell-37-1-9-2]). These findings raise the question whether or not other WWE domain-containing E3 ligases also target various PARP substrates for ubiquitination and degradation. Moreover, RNF146 only binds to poly-ADP-ribose, but not mono-ADP-ribose ([@b73-molcell-37-1-9-2]), indicating that there may be other yet-to-be-identified E3 ligases that recognize mono-ADP-ribose and mediate proteasome-dependent degradation of mono-ribosylated substrates.

The third group of WWE domain-containing proteins is actually just one protein: DDHD2. This protein has one WWE domain and one DDHD phospholipase domain and is involved in inter-cellular membrane trafficking at the Golgi complex/endoplasmic reticulum interface ([@b20-molcell-37-1-9-2]).

BRCT and FHA domains
--------------------

BRCT and FHA domains are known phosphopeptide binding domains that participate in DNA damage response and cell cycle regulations ([@b19-molcell-37-1-9-2]; [@b38-molcell-37-1-9-2]; [@b75-molcell-37-1-9-2]). However, recent studies demonstrated that the FHA domains of APTX and PNKP, and the BRCT domains of BARD1, DNA Ligase 4, XRCC1 and NBS1 recognize Poly-ADP-ribose, and this PAR-binding ability is important for their recruitment to DNA damage sites ([@b37-molcell-37-1-9-2]; [@b37-molcell-37-1-9-2]). These studies further expand PAR-binding motifs and highlight the roles of ADP-ribosylation in signaling transduction.

PAR-REMOVING ENZYMES
====================

Both mono-ADP-ribosylation and PARsylation can be reversed by PAR-removing enzymes. PAR glycohydrolase (PARG) is the best known PAR removing enzyme. It possesses both endoglycohydrolase and exoglycohydrolase activity and is responsible for hydrolysis of ribose-ribose bonds within poly-ADP-ribose chains ([@b27-molcell-37-1-9-2]). PARG cleaves poly-ADP-ribose chains into free chains or mono-ADP-riboses ([@b41-molcell-37-1-9-2]; [@b68-molcell-37-1-9-2]). PARG has several isoforms owing to alternative splicing: a very active full-length 110-kDa nuclear protein, a shorter 102-kDa nuclear isoform, and a 60-kDa variant located in mitochondria due to the lack of an NLS (nuclear localization signal) at its N-terminal region. This mitochondrial variant of PARG cannot catalyze PAR degradation ([@b45-molcell-37-1-9-2]). PARG knockout leads to embryonic lethality in mice and PARG-deficient cells are sensitive to genotoxic stress ([@b34-molcell-37-1-9-2]), demonstrating critical functions of PARG in genome maintenance.

Another PAR-removing enzyme is the 39-kDa protein ADP-ribosyl hydrolase 3, which generates free ADP-ribose from the poly-ADP-ribose chain but cannot cleave the ADP-ribose-protein bond, therefore leading to the formation of mono-ADP-ribosylated proteins ([@b46-molcell-37-1-9-2]; [@b49-molcell-37-1-9-2]). The enzymes that can remove mono-ADP-ribose were unknown for a long time. Recently, several groups reported that some macrodomain-containing proteins, MacroD1, MacroD2, and C6orf130, have ADP-ribose hydrolase activity and can remove mono-ADP-ribose from substrate proteins by cleaving the ribose-protein bond ([@b29-molcell-37-1-9-2]; [@b57-molcell-37-1-9-2]; [@b67-molcell-37-1-9-2]), These findings significantly contributed to the understanding of PAR removal and recycle ([Fig. 4](#f4-molcell-37-1-9-2){ref-type="fig"}).

CONCLUSION
==========

ADP-ribosylation is one of the protein posttranslational modifications that has been studied for a long time. However, most of the studies focused on PARP1, which is the ubiquitous and best characterized member of the PARP family. Recent studies started to elucidate the biochemical activities and biological functions of other PARPs, which have greatly increased our knowledge of diverse functions of ADP-ribosylation in a variety of cellular processes.

The biology of ADP-ribosylation includes the synthesis, recognition, degradation, and recycling of this important biological moiety. All 17 PARPs are characterized by PARP domain, but they function differently in ADP-ribose synthesis ([@b63-molcell-37-1-9-2]). While PARP1-PARP4 and tankyrase1/2 have poly-ADP-ribosylation activity, PARP9 and PARP13 are thought to be catalytically inactive, while other PARPs exhibit mono-ADP-ribosylation activity. Besides the well-studied PARP1, researchers made exciting discoveries about the function of tankyrases in targeting axin degradation and activation of the Wnt pathway. However, for most PARPs, their functions, substrates, and how they are regulated are still largely unknown. Furthermore, the PAR recognition domains have now been appreciated as important mediators involved in signal transduction *via* ADP-ribosylation. Specifically, the PBM and a subset of FHA and BRCT domains are critically important for the recruitment of checkpoint and repair proteins to DNA damage sites, while the WWE domain of RNF146 is required for E3 ligase-mediated proteasomal degradation of ribosylated proteins. It remains to be determined whether there are new PAR-binding domains and PAR-binding proteins. On the other hand, PARG is the main enzyme that hydrolyzes ribose-ribose bonds. Recent discoveries that macrodomain-containing proteins have the activity to cleave mono-ADP-ribose from substrates provide another piece of the puzzle and underscore the reversible nature of ADP-ribosylation as a signaling moiety. How the activities of PARG and macrodomain-containing proteins are regulated and coordinated is another challenge the field is facing.
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![The domain organization of PARPs. The PARP domain is the catalytic domain and is required for NAD^+^ binding and PAR synthesis. The zinc finger domain is an DNA-binding domain. The BRCA1 C terminus (BRCT), ankyrin repeat (ANK) and sterile α-motif (SAM) domains are protein-protein interaction domains. The CCCH domain is a Cys-Cys-Cys-His zinc finger domain. The WGR is a functionally unknown domain. Macro and WWE are PAR-binding domains.](molcell-37-1-2-f1){#f1-molcell-37-1-9-2}

![Schematic diagrams of macro domain-containing proteins. The PARP is the catalytic domain and is required for NAD^+^ binding and PAR synthesis. Macro and WWE are PAR-binding domains. H2A is the domain in MacroH2As that shares extensive sequence homolog with histone H2A. DEXD is a DEAD-like helicase domain, which contains ATP-binding region. HELIC is the helicase superfamily c-terminal domain. SEC14 is the Sec14p-like lipid-binding domain.](molcell-37-1-2-f2){#f2-molcell-37-1-9-2}

![Schematic diagrams of WWE domain-containing proteins. The PARP is the catalytic domain and is required for NAD^+^ binding and PAR synthesis. The sterile α-motif (SAM) is a protein-protein interaction domain. The CCCH is a Cys-Cys-Cys-His zinc finger domain. Macro and WWE are PAR-binding domains. The RING domain has E3 ubiquitin ligase activity. HECT domain (homologous to E6-AP carboxyl terminus) also contains E3 ligase activity. DDHD (Asp and His-containing domain) has phospholipase activity.](molcell-37-1-2-f3){#f3-molcell-37-1-9-2}
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